Patents
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
03/2002
03/14/2002US20020031561 Chemical composition for aiding the absorption, binding and elimination of undigested fat
03/14/2002US20020031560 Stabilized St. John's wort; antidepressant
03/14/2002US20020031558 Preparation of aqueous clear solution dosage forms with bile acids
03/14/2002US20020031557 Ascorbic acid composition and method for treatment of aging or damaged skin
03/14/2002US20020031550 Nervous system disorders; Alzheimer's disease
03/14/2002US20020031549 Side effect reduction; antiepideptic agents, headaches, bipolar disorders
03/14/2002US20020031548 Pharmaceutical compositions of estrogenic agents
03/14/2002US20020031544 Antiinflammatory agents
03/14/2002US20020031542 Isoprene styrene block copolymer, a rosin-based resin, a plasticizer, polyisobutylene, an antioxidant; bandages
03/14/2002US20020031539 Oxidized forms of retinoic acid as ligands for peroxisome proliferator activated receptor gamma
03/14/2002US20020031537 Use of nitrogen-containing complexing agents for deodorization and antimicrobial treatment of the skin and textile fibre materials
03/14/2002US20020031535 Copper, copper sulfate, sodium carbonate, turpentine, ethanol, and water
03/14/2002US20020031524 Polysaccharide and complexes contain glucose and any of galactose, rhamnose, mannose, arabinose, n-acetyl glucosamine and n-acetyl galactosamine; increase proliferation of splenocytes and cytokine production; immunomodulators
03/14/2002US20020031517 Administering an inhibitor of GDF-8, or a related member of Transforming Growth Factor-beta superfamily of structurally-related growth factors
03/14/2002US20020031512 Inhibiting immunological activation of keratinocytes by administering molecule that binds to CD40 but does not activate CD40-expressing keratinocytes
03/14/2002US20020031505 Antitumor compositions containing taxane derivatives
03/14/2002US20020031490 Method for preparing resinates
03/14/2002US20020031480 Aerosolizing a hydrofluoroalkane (HFA)/THC composition to provide droplets respirable by a lung of a patient, and administering; inhalers; treating pain, cachexia, migraines, nausea,muscle spasticity
03/14/2002US20020031479 Medicaments
03/14/2002DE4319554C2 Verwendung von Menthol zur peroralen entzündungshemmenden Behandlung von Asthma bronchiale The use of menthol for oral anti-inflammatory treatment of bronchial asthma
03/14/2002DE10141749A1 Inhibiting or stimulating angiogenesis by modulating the kinin B1 receptor, useful e.g. for treating solid tumors, macular degeneration, diabetic retinopathy or cardiac infarction
03/14/2002DE10048969A1 Verwendung von Flupirtin zur Tinnitusbehandlung Use of flupirtine for tinnitus treatment
03/14/2002DE10043667A1 2-Guanidino-4-aryl-chinazoline 2-guanidino-4-aryl-quinazolines
03/14/2002DE10043659A1 Arylpiperazinderivate Arylpiperazinderivate
03/14/2002DE10043456A1 Verwendung von Ectoin oder Ectoin-Derivaten zur Stabilisierung von p53 Use of ectoine or ectoine derivatives for the stabilization of p53
03/14/2002DE10043227A1 Neuartiges entwicklungsbiologisches Gen Novel biological developmental gene
03/14/2002DE10043124A1 Verfahren zur Diagnostik von neuronalen Erkrankungen sowie zur Behandlung der defizienten primären Hämostase Method for the diagnosis of neural disorders and for the treatment of primary hemostasis deficiency
03/14/2002DE10042997A1 Thienopyrimidine Thienopyrimidines
03/14/2002DE10042833A1 Feste Zubereitungen mit einer Multi-Kern Struktur Solid preparations with a multi-core structure
03/14/2002DE10042655A1 Verfahren zur Herstellung von Inhibitoren der Zell-Adhäsion Process for the preparation of inhibitors of cell adhesion
03/14/2002DE10042137A1 sgk2 und sgk3 als diagnostische und therapeutische Targets sgk2 and sgk3 as diagnostic and therapeutic targets
03/14/2002DE10041479A1 Neue pharmazeutische Zusammensetzung zur Verabreichung von N-0923 Novel pharmaceutical composition for the administration of N-0923
03/14/2002DE10041478A1 Neue pharmazeutische Zusammensetzung New pharmaceutical composition
03/14/2002DE10041402A1 Neue Verbindungen, die Faktor Xa-Aktivität inhibieren Novel compounds which inhibit factor Xa activity
03/14/2002DE10040901A1 Neue Phenyl- und Phenylalkyl-substituierte Ethanolamine und Ethylendiamine New phenyl and phenylalkyl substituted ethanolamines and ethylenediamines
03/14/2002DE10023486C1 Ortho substituierte Anthranilsäureamide und deren Verwendung als Arzneimittel Ortho-substituted anthranilic acid amides and their use as medicaments
03/14/2002CA2422200A1 Methods for inhibiting decrease in transdermal drug flux by inhibition of pathway closure
03/14/2002CA2422198A1 Substituted hydrazine derivatives
03/14/2002CA2422159A1 Novel polymorphic form of 17-beta-(n-ter.butyl carbamoyl)-4-aza-5-alpha-androst-1-en-3-one and a process for preparing it
03/14/2002CA2422157A1 Inhibitors of serine protease activity of matriptase or mtsp1
03/14/2002CA2421834A1 Use of carp inhibitors for the treatment of heart diseases
03/14/2002CA2421723A1 Stat3 agonists and antagonists and therapeutic uses thereof
03/14/2002CA2421718A1 Protein tyrosine phosphatase inhibitor
03/14/2002CA2421584A1 Gene therapy for cardiac arrythmias
03/14/2002CA2421581A1 Benzene tricarboxylic acid amides as insulin receptor activators
03/14/2002CA2421510A1 A method for treating allergies using substituted pyrazoles
03/14/2002CA2421506A1 Cyclic and acyclic amidines and pharmaceutical compositions containing them for use as progesterone receptor binding agents
03/14/2002CA2421505A1 Method for treating allergies using substituted pyrazoles
03/14/2002CA2421502A1 A method for treating allergies
03/14/2002CA2421493A1 A method for treating allergies using substituted pyrazoles
03/14/2002CA2421380A1 Biopanning and rapid analysis of selective interactive ligands (brasil)
03/14/2002CA2421285A1 Methods for analyzing and using data from hypertensive patients
03/14/2002CA2421271A1 Human and mouse targeting peptides identified by phage display
03/14/2002CA2421213A1 The hydrochloride salt of 5-[4-[2-(n-methyl-n-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione
03/14/2002CA2421200A1 Adenoviral targeting and manipulation of immune system response using targeting peptides
03/14/2002CA2421195A1 Compositions and methods for targeting peptides in humans in vivo
03/14/2002CA2421191A1 Methods and compositions for in vitro targeting
03/14/2002CA2421018A1 Dihydroxy open-acid salt of simvastatin
03/14/2002CA2420993A1 Methods and pharmaceutical compositions employing desmethylselegiline to treat neoplastic diseases or conditions
03/14/2002CA2420890A1 Antithrombotic compositions
03/14/2002CA2420703A1 Quinoline and quinazoline derivatives as ligands for the neuropeptide y receptor
03/14/2002CA2419966A1 Aryl substituted tetrahydroindazoles and their use as ligands for the gaba-a receptor
03/14/2002CA2419958A1 Substituted fused pyrroleimines and pyrazoleimines
03/14/2002CA2419653A1 Prevention of acute sinusitis and sinus attack
03/14/2002CA2419601A1 The treatment of inflammatory disorders
03/14/2002CA2419590A1 Exemestane as chemopreventing agent
03/14/2002CA2419563A1 Chimeric antisense of arabinofuranose analogue and deoxyribose nucleotides
03/14/2002CA2417594A1 Bicyclic pyrrolyl amides as glucogen phosphorylase inhibitors
03/14/2002CA2417258A1 Flavoring systems for pharmaceutical compositions and methods of making such compositions
03/14/2002CA2417177A1 Spiroheterocyclic nitriles useful as reversible inhibitors of cysteine proteases
03/14/2002CA2416336A1 Multivalent neuraminidase inhibitor conjugates
03/14/2002CA2390156A1 A process for producing an epoxy compound, a flavor and fragrance composition containing the compound, and foods & drinks,perfumes,cosmetics a nd tobaccos respectively containingthe composition
03/14/2002CA2389602A1 Methods and compositions for potentiating cancer chemotherapeutic agents
03/13/2002EP1186672A2 Polymorphisms in the human organic anion transporter C (OATP-C) gene
03/13/2002EP1186610A1 Dicarboxylato diammine platinum derivatives and compositions comprising them as anti-tumor agents
03/13/2002EP1186607A1 Optically active pyrrolopyridazine compounds
03/13/2002EP1186606A1 Epothilone derivatives, their preparation and utilization
03/13/2002EP1186603A2 Processes for preparing endothelin antagonists
03/13/2002EP1186602A2 Omeprazole sodium salt and its use as anti-ulcer agent
03/13/2002EP1186318A2 Combination, for treating depression and anxiety, containing a 5HT1d receptor antagonist and aCNS penetrant NK-1 receptor antagonist
03/13/2002EP1186304A2 Pharmaceutical combinations for the treatment of stroke and traumatic brain injury
03/13/2002EP1186303A2 Pharmaceutical combinations, for the treatment of stroke and traumatic brain injury, containing a neutrophil inhibiting factor and an selective NMDA-NR2B receptor antagonist
03/13/2002EP1186302A1 Ocular tension lowering composition for topical adminstration
03/13/2002EP1186298A2 Structures and methods for administering cannabis to patients
03/13/2002EP1186297A2 Agent for preventing, improving or treating hypertension
03/13/2002EP1186296A1 Mag expression promoters
03/13/2002EP1186295A1 Pharmaceutical preparations containing extracts of soy isoflavone and probiotic micro-organisms
03/13/2002EP1186294A2 Ferulic acid and caffeic or chlorogenic acids containing compositions for alleviating hypertension or preventing a rise in blood pressure
03/13/2002EP1186293A2 Intermittent administration of a growth hormone secretagogue
03/13/2002EP1186292A2 Solid composition with a multi-core structure
03/13/2002EP1186290A2 Method and device for treating scars
03/13/2002EP1186287A1 Hair growth or hair formation controlling agents
03/13/2002EP1185948A1 Method for screening and producing compound libraries
03/13/2002EP1185862A2 Method and compositions relating to insulin resistance disorders
03/13/2002EP1185700A1 49 human secreted proteins
03/13/2002EP1185696A1 Antisense oligonucleotide modulation of human protein kinase c-delta expression
03/13/2002EP1185694A1 49 human secreted proteins
03/13/2002EP1185691A1 Neisseria genomic sequences and methods of their use
03/13/2002EP1185687A1 Methods for increasing t cell proliferation
03/13/2002EP1185681A1 High specificity hairpin antisense oligonucleotides